ViroStatics is focused on both oncology and virology R&D.
Oncology: Caring for those patients without viable therapeutic options we are developing new compounds for the treatment of aggressive cancers with high unmet need. Our advanced preclinical candidate Myrtleciclib is open for licensing to a pharmaceutical company or for investment.
Wide geographic coverage of composition of matter patents. Overall patent protection planned to be extended up to 2043.
Virology: Leveraging on its wide experience in the fight against the HIV/AIDS virus, our researchers have demonstrated how drug combinations work better than single drugs, thus inducing the first functional cure of an HIV patient, the well known Berlin patient (NEJM, 1999). ViroStatics retains the technical skills (complex experimental designs, rapid and accurate execution of the experiments, rigorous reading of the results) to investigate therapeutic solutions to viral pandemics, including COVID-19.